{
  "analysis_timestamp": "2026-01-09T03:11:47.235029",
  "analyses": {
    "benefit_factor": {
      "benefit_sub_factor": "Off label",
      "weight": 10,
      "score": 1,
      "weighted_score": 10,
      "cdsco_approved": false,
      "usfda_approved": false
    },
    "market_experience": {
      "experience_sub_factor": "Established indication (>5Y, approved widely)",
      "weight": 90,
      "score": 5,
      "weighted_score": 450,
      "years_in_market": 44
    },
    "pubmed_evidence": {
      "evidence_sub_factor": "Low evidence (limited data, uncertain)",
      "weight": 30,
      "score": 1,
      "weighted_score": 30,
      "rct_count": 0
    },
    "raw_data": {
      "drug": "Furosemide",
      "diagnosis": "Hyperlipidemia",
      "patient_info": {
        "age": 60,
        "gender": "Male",
        "diagnosis": "Hyperlipidemia, Chronic Liver Disease",
        "condition": "decompensated cirrhosis",
        "allergies": [],
        "date_of_assessment": "2026-01-06"
      },
      "regulatory": {
        "drug": "Furosemide",
        "condition": "Hyperlipidemia",
        "cdsco_approved": false,
        "usfda_approved": false,
        "output": "Furosemide is not approved for use in Hyperlipidemia as per the CDSCO (Indian health regulatory body) and also as per USFDA's USPI (United States Prescriber information). Please review the iBR score and consider alternative medications that are approved by regulatory bodies for treating Hyperlipidemia."
      },
      "market_experience": {
        "found": true,
        "generic_name": "FUROSEMIDE",
        "approval_date": "19-May-1981",
        "years": 44,
        "output": "FUROSEMIDE is first approved by USFDA on 19-May-1981 and first approved by CDSCO on [CDSCO approval date not available]. FUROSEMIDE is in the market for more than 44 years of post-market experience."
      },
      "pubmed_evidence": {
        "rct_count": 0,
        "top_conclusions": []
      }
    }
  }
}